1. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study 
Michael Kasperkiewicz, MD, Enno Schmidt, MD, PhD, Yvonne Frambach, MD, Christian Rose, MD, Markus Meier, MD, Martin Nitschke, MD, Thomas M. Falk, PhD, Kristian Reich, MD, Ralf J. Ludwig, MD, Detlef Zillikens, MD 
Journal of Allergy and Clinical Immunology 
Volume 127, Issue 1, Pages e6 (January 2011)
DOI: /j.jaci
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Immunoadsorption (IA) improves clinical disease in AD. A, Presentation before initiation of IA (week 1) and clinical response at week 5 and 13 in patient 8. B, Time-dependent mean relative SCORAD reduction after IA. Arrows indicate first and second cycle of IA. ∗P < .001.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Immunoadsorption (IA) reduces skin-bound IgE. A, Representative immunostaining of anti-IgE antibody in sections of lesional skin biopsies of a patient with AD before initiation of IA (week 1) as well as at weeks 5 and 13 (×200). B, Statistical analysis of semiquantitative scoring of staining intensity of anti-IgE antibody.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Immunoadsorption (IA) reduces hyperkeratosis, acanthosis, spongiosis, and dermal infiltrate in patients with AD. A, Representative hematoxylin and eosin-stained skin biopsy specimens before initiation of IA (week 1) as well as at weeks 5 and 13 (×200). B, Statistical analysis of semiquantitative scoring of histopathologic parameters.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Immunoadsorption (IA) reduces skin infiltration by T cells, antigen-presenting cells, and proliferating cells in patients with AD. A, Representative immunostaining of anti-CD3, anti-CD4, anti-CD1a, anti–HLA-DR, and anti-MIB1 antibody in skin of patients with AD before initiation of IA (week 1) as well as at weeks 5 and 13 (×200). B, Statistical analysis of semiquantitative scoring of skin-infiltrating and proliferating cells.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions